Natera, Inc. Common Stock
$369.39
$3.08 (+0.84%)
$358.90Day Range$369.69
Key Statistics
Market Cap
$53.25B
Shares Outstanding
144.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 2, 2015
Round Lot
100
Locale
US
Trading Data
Day Open
$365.78
Day High
$369.69
Day Low
$358.90
Volume
3.72M
VWAP
$367.25
Prev Close
$366.31
Transactions
--
Acc. Volume
--
About Natera, Inc. Common Stock
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
SERVICES-MEDICAL LABORATORIESSIC 80716,140 employees13011 MCCALLEN PASS, AUSTIN, TX, 78753650-249-9090IPO Jul 2, 2015US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001604821
- Composite FIGI
- BBG001J1BQ86
- Share Class FIGI
- BBG001V0FSF8
- Ticker Root
- NTRA
- SIC Code
- 8071
About Natera, Inc. Common Stock (NTRA) Stock
Natera, Inc. Common Stock (NTRA) closed the 2026-09-18 session at $369.39, up 0.84% versus the previous close (+3.08). The stock opened at $365.78 and traded between $358.90 and $369.69 during that session. Session trading volume was 3.7M shares. The volume-weighted average price (VWAP) is $367.25.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Natera, Inc. Common Stock has a market capitalization of $53.25 billion. The company operates in the SERVICES-MEDICAL LABORATORIES industry classification. NTRA is listed on the XNAS exchange. The company employs approximately 6,140 people. Natera, Inc. Common Stock is headquartered in AUSTIN, TX. The recorded listing date is 2015-07-02.
On this page you can find market NTRA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the SERVICES-MEDICAL LABORATORIES sector.